Eastern Cooperative Oncology Group:

You can learn more about this trial by viewing a short informational video featuring Dr. Kathy Miller, the study chair for this trial:

• E5103 Real Media Video
• E5103 Windows Media Video

Note to institutions: Use of these videos for patient education requires approval of your institution's IRB.

This is a randomized Phase III trial to evaluate the potential benefit of adding bevacizumab to standard chemotherapy for breast cancer patients with high risk of relapse. Patients participating in this study will be randomized, that is, assigned by chance, to one of three treatment groups:

• Group 1 will receive standard chemotherapy, Doxorubicin and Cyclophosphamide for twelve weeks followed by twelve weeks of Paclitaxel.
• Group 2 will receive the same therapy as group 1, but will also receive bevaizumab at three week intervals throughout the two twelve week treatment periods.
• Group 3 will receive the same treatments as group 2. After completion of the two twelve week treatment periods, group 3 will continue to receive bevacizumab every three weeks for thirty weeks.

It is not known at this time whether there is any benefit that would result from adding bevacizumab to the standard therapy or from increasing the number of bevacizumab treatments beyond the initial twenty four month period. These are the questions that we hope will be answered by this trial.

You can learn more about breast cancer treatment options by visiting these web sites:

• National Cancer Institute Breast Cancer Infomration
• Breast Cancer Network of Strength (formerly Y-ME)
• Susan G. Komen For The Cure

Information about cancer clinical trials can be found at:

National Cancer Institute Clinical Trials Information

CancerTrialsHelp - Coalition of Cancer Cooperative Groups